Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 3:54 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 59 matching trials from the live ClinicalTrials.gov search.
Conditions
Atrial Fibrillation, Stroke
Interventions
Catheter Ablation, Market-approved AVNB, OAC and AAD
Device · Drug
Lead sponsor
Kansas City Heart Rhythm Research Foundation
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
7
States / cities
Overland Park, Kansas • Independence, Missouri • Kansas City, Missouri
Completed Phase 1 Interventional Accepts healthy volunteers Results available

CiPA Phase 1 ECG Biomarker Validation Study

NCT03070470
Conditions
Drug-induced QT Prolongation, Pharmacokinetics, Pharmacodynamics
Interventions
Ranolazine, Verapamil, Lopinavir / Ritonavir, Chloroquine, Placebo, Dofetilide and Diltiazem
Drug
Lead sponsor
Food and Drug Administration (FDA)
Federal
Eligibility
18 Years to 50 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
West Bend, Wisconsin
Conditions
Hypertension, Heart Failure
Interventions
Clevidipine, Standard of Care IV antihypertensive
Drug
Lead sponsor
The Medicines Company
Industry
Eligibility
18 Years and older
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
9
States / cities
Montgomery, Alabama • Inglewood, California • Baton Rouge, Louisiana + 6 more
Conditions
Hypertensive Renal Disease
Interventions
USUAL - take your BP Meds as you usually do, HS DOSING, ADD On Dosing
Behavioral · Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
16
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 12 more
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of Diltiazem Administration on CP-945,598 Pharmacokinetics

NCT00645463
Conditions
Obesity
Interventions
CP-945,598
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Ann Arbor, Michigan
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Drug-Drug Interaction of Cardizem LA (Diltiazem Hydrochloride) on Pitavastatin

NCT01422382
Conditions
Healthy
Interventions
Pitavastatin (NK-104), Diltiazem (Cardizem LA) 240 mg QD
Drug
Lead sponsor
Kowa Research Institute, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Austin, Texas
Conditions
Atrial Fibrillation, Heart Failure
Interventions
FDA approved rate and rhythm control drugs, AV Node ablation and device implant
Drug · Device
Lead sponsor
Mayo Clinic
Other
Eligibility
65 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
5
States / cities
Scottsdale, Arizona • Evansville, Indiana • Rochester, Minnesota + 2 more
Not listed Phase 1 Interventional Accepts healthy volunteers

Topical Safety Study of Topical Diltiazem Hydrochloride

NCT01816529
Conditions
Diltiazem Skin Sensitivity.
Interventions
Diltiazem Hydrochloride 2% Cream, Vehicle Cream, 0.1% solution of sodium lauryl sulfate (SLS), Saline (0.9%)
Drug
Lead sponsor
Ventrus Biosciences, Inc
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Paramus, New Jersey
Conditions
Atrial Fibrillation
Interventions
Beta-blocker strategy, Calcium channel blocker strategy, Physician preference strategy
Drug
Lead sponsor
Boston University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Healthy
Interventions
MK-6552, Diltiazem
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Lenexa, Kansas
Conditions
Healthy Subjects
Interventions
E2027, Diltiazem ER
Drug
Lead sponsor
Eisai Co., Ltd.
Industry
Eligibility
18 Years to 50 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
San Antonio, Texas
Conditions
Hypertension, COVID
Interventions
ACEI/ARB, Non-ACEI/ARB, ACEI, ARB
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
22,213 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Salt Lake City, Utah
Conditions
Heart; Dysfunction Postoperative, Cardiac Surgery
Interventions
Ranolazine, Placebo
Drug
Lead sponsor
Corewell Health East
Other
Eligibility
22 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
2
States / cities
Royal Oak, Michigan • Troy, Michigan
Conditions
Supraventricular Tachycardia (SVT)
Interventions
IV adenosine, IV diltiazem
Drug
Lead sponsor
University of Iowa
Other
Eligibility
18 Years to 100 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Iowa City, Iowa
Conditions
Healthy Volunteers, Pharmacologic Action
Interventions
Group 1 AZD3293, Group 2 AZD3293, Group 3 AZD3293, Group 1 Itraconazole, Group 2 Diltiazem, Group 3 Midazolam
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Cypress, California
Conditions
Malignant Digestive System Neoplasm
Interventions
Biospecimen Collection, Capecitabine, Diltiazem Hydrochloride, Electrocardiogram, Fluorouracil, Holter Monitoring, Isosorbide Mononitrate, Medical Device Usage and Evaluation, Placebo Administration, Questionnaire Administration
Procedure · Drug · Device + 1 more
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Healthy
Interventions
Nemtabrutinib, Diltiazem
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Madison, Wisconsin
Conditions
CLARITHROMYCIN/DILTIAZEM [VA Drug Interaction]
Interventions
Clarithromycin XL, 2% Diltiazem
Drug
Lead sponsor
Ventrus Biosciences, Inc
Industry
Eligibility
18 Years to 60 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Paramus, New Jersey
Conditions
Microvascular Angina
Interventions
Ranolazine, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
30 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
New Haven, Connecticut
Conditions
Health Participants
Interventions
BMS-986209, BMS-986209 Placebo, Itraconazole, Diltiazem
Drug · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 55 Years
Enrollment
114 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Austin, Texas
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Clinical Trial of MK-4082 in Healthy Participants (MK-4082-005)

NCT07697625
Conditions
Healthy
Interventions
MK-4082, Diltiazem, Rescue medication
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Anaheim, California
Conditions
Prostatic Neoplasms
Interventions
MK-5684, Prednisone, Fludrocortisone acetate, Diltiazem hydrocholoride
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Tempe, Arizona
Conditions
Heart Failure With Preserved Ejection Fraction
Interventions
Ranolazine, Placebo
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
San Diego, California
Conditions
Heart Rate and Rhythm Disorders
Interventions
Metoprolol, Diltiazem
Drug
Lead sponsor
Antonios Likourezos
Other
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Brooklyn, New York